期刊文献+

子宫内膜异位症患者血清基质金属蛋白酶-9及其诱导因子血管内皮生长因子的变化 被引量:4

MMP-9,EMMPRIN and VEGEF in plasma of women with endometriosis
下载PDF
导出
摘要 目的探讨细胞外基质金属蛋白酶诱导因子(EMMPRIN)、基质金属蛋白酶-9(MMP-9)、血管内皮生长因子(VEGF)在子宫内膜异位症患者血清中表达水平的变化及其临床意义。方法收集70例子宫内膜异位症(EMs)患者(其中Ⅰ期10例、Ⅱ期14例、Ⅲ期28例、Ⅳ期18例)和20例对照组患者的血清,以及30例EMs患者手术加药物治疗后的血清标本,采用酶联免疫吸附法(ELISA)定量检测血清中EMMPRIN、MMP-9、VEGF的表达水平。结果EMs患者血清中三者的表达水平高于对照组(P〈0.05),早期患者(Ⅰ~Ⅱ期)血清中三者低于Ⅲ~Ⅳ期(P〈0.05);手术加药物治疗后EMs患者血清VEGF水平可显著性降低;血清VEGF水平与临床分期呈直线正相关关系(P〈0.05,r=0.396)。结论EMMPRIN、MMP-9、VEGF在EMs发病中起着重要作用,检测血清中VEGF水平对于EMs患者随访监测及评价临床疗效有一定价值。 Objective To study the significance of detection of EMMPRIN,MMP-9 and VEGF in plasma of women with endometriosis.Methods We measured the concentrations of EMMPRIN,MMP-9 and VEGF in plasma of women with endometriosis(n=70) and compared them with those in a control group(n=20),as assessed by enzyme-linked immunosorbent assay(ELISA).Results The concentrations of MMPRIN,MMP-9 and VEGF in the plasma of patients with endometriosis was higher than that in the control group(P 0.05).The same result appeared in advanced stage compared with early stage.Positive correlations between stage of disease with EMMPRIN,MMP-9 and VEGF were found(P 0.01,P =0.396).The concentrations of VEGF after treatment were significantly lower(P 0.05) in plasma of endometriosis patients.Conclusion These results suggest that EMMPRIN,MMP-9 and VEGF may play an important role in the pathogenesis of the disease.Detection of EMMPRIN,MMP-9 and VEGF,especially VEGF in plasma of women with endometriosis has important clinical significance.
出处 《济宁医学院学报》 2010年第2期92-93,96,共3页 Journal of Jining Medical University
基金 济宁市科技局课题(济科发[2007]50号)
关键词 子宫内膜异位症 EMMPRIN、MMP-9、VEGF 血清 酶联免疫吸附法 Endometrosis(EMs) EMMPRIN MMP-9 VEGF Plasma Enzyme linked immunosorbent assay(ELISA)
  • 相关文献

参考文献5

  • 1李东.血清基质金属蛋白酶类检测的临床应用[J].国外医学(临床生物化学与检验学分册),2002,23(2):100-101. 被引量:5
  • 2Jinga D,Stefanescu M,Blidaru A,et al.Serum levels of matrix-metalloproteinases MMP-2 and MMP-9 and their tissue natural inhibitors in breast tumors[J].Roum Arch Microbiol Immunol,2004,63(3-4):141.
  • 3Biswas C,ZhangY,Decastro R,et al.The human tumor cell-derived collagenase stimulatory factor(Renamed EMMPRIN) is a member of the immunoglobulin[J].Cancer Res,1995,55:434.
  • 4Szamatowicz J,Laudanski P,Tomaszewska I,et al.Matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1:a possible role in the pathogenesis of endometriosis[J].Hum Reprod,2002,17(2):284.
  • 5Abdallah MAKang S,Nakajima ST,et al.Matrix metalloproteinase-9 activity in the plasma of patients after surgical resection of endometriosis[J].Fertil Steril,2006,85(6):1847.

二级参考文献16

  • 1Arthur MJP. Murawaki Y. Serum matrix metalloproteinase-1 in patients with chronic viral hepatitis[J]. J Gastroenterol Hepatol, 1999,14(2): 138-144.
  • 2Kasahara A, Hayashi N. Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C. Relationship to interferon response[J]. J Hepatol, 1997, 26(3):574-583.
  • 3Ylisirnio S, Hoyhtya M. Matrix met alloproteinases -2 ,-9 and tissue inhibitors of matalloproteinases -1,-2 in lung cancer-TIMP-1 as a prognostic marker[J]. Anticancer Res, 2000,20(2B) :1311-1316.
  • 4Oberg A, Hoyhtya M, Tavelin B, et al. A Limitid value of preoperative serum analyses of matrix metalloproteinases(MMP-2,MMP-9) and tissue in hibitors of matrix metalloproteinases (TIMP-1 ,TIMP-2) in colorectal cancer[J]. Gut,1998,42(5):715-720.
  • 5Gohji K, Fujimoto N, et al. Serum matrix metalloproteinase-2 and its density in men with prostate cancer as a new prdeictor of disease extension [J]. Int J Cancer,1998,20,79(1):96-101.
  • 6Endo K, Maehara Y, Baba H, et al.Elevated levels of serum and plasma metalloproteinases in patients with gastric cancer [J]. Anticancer Res,1997,17 (3C): 2253-2258.
  • 7Kinoshita M, Sumiya M. Serum matrix metalloproteinase-3 and fibrin degradation product levels correlate with clinical disease activity in rheumatoid arthritis[J]. Clin Exp Rheumatol, 1998,16(5): 533-540.
  • 8Kotajima L, Aotsuka S, Fujimani M,et al. Increased levels of matrix metalloproteinase-3 in sera from patients with active lupus nephritis[J]. Clin Exp Rheumatol, 1998, 16 (4): 409-415.
  • 9Matsuyama T. Tissue inhibitor of mealloproteinases-1 and matrix metalloproteinases-3 in Japanese healthy children and in Kawasaki disease and their clinical usefulness in juvenile rheumatoid arthritis[J]. Pediatr Int,1999,41(3) :239-245.
  • 10Nishida T. Kinetics of tissue and serum matrix metalloproteinase-3 and tissue inhibitor of matalloproteinases1 in intervertabral disc degeneration and disc herniation[J]. Kurume Med J,1999,46(1) :39-50.

共引文献4

同被引文献43

  • 1陆品红,刘嘉茵.TNF-α、sTNFRⅠ对子宫内膜异位症在位内膜基质细胞的影响[J].南京医科大学学报(自然科学版),2006,26(1):51-54. 被引量:3
  • 2Kyama CM ,Mihyi A,Simsa P,et . Non-steroidtargets in the di- agnosis and treatment of endometriosis. Curr Med Chem,200$, 15: 1006-1017.
  • 3乐杰.子宫内膜异位症和子宫腺肌病.妇产科学.第6版.北京:人民卫生出版社,2006:354-358.
  • 4Lin J, Gu Y. Effect of monocyte chemoattractant protein-1 and estra- diol on the secretion of vascular endothelial growth factor in endome- trial stromal cells in vitro. Fertil Steri1,2005,84:1793-1796.
  • 5秦风雪,张英娥,刘听.MMP-2与VECF在子宫腺肌病中的表达和意义.中国妇幼保踺,2007,22:1794-1796.
  • 6Bourlev V, Volkov N, Pavloviteh S, et al. The relationship between microvessel density, proliferative activity and expression of vascular endothelial growth factor-A and its receptors in eutopic endometrium and endometriotic lesions. Reproduction ,2006,132:501-509.
  • 7Gazvani R, Smith L, Fowler PA. Effect ff inter|eukin-8 ( lL-8 ) , anti- IL-8, and IL-12 on endometrial cell survival in combined endometrial gland and stromal cell cultures derived from women with and without endometriosis. Fertil Steril 2002,77:62-67.
  • 8Xavier P, Belo L, Beires J, et al. Serum levels of VEGF and TNF- alpha and their association with C-reactive protein in patients with endometriosis. Arch Gynecol Obstet ,2006,273:227-231.
  • 9Olszynski K, Zimowska M. Structure and function of matrix metal loproteinases. Postepy Biochem ,2009,55:76-84.
  • 10Viisse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases : structure, function, and biochemistry. Circ Res, 2003.92 : 827-839.

引证文献4

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部